Biomarin Pharmaceutical (BMRN) Long-Term Deferred Tax (2010 - 2026)

Biomarin Pharmaceutical has disclosed Long-Term Deferred Tax across 17 years of filings, most recently posting $1.5 billion for Q1 2026.

• Quarterly Long-Term Deferred Tax rose 2.74% year-over-year to $1.5 billion in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $1.5 billion (up 2.74% YoY) and the FY2025 annual result came in at $1.5 billion, up 1.3% from the prior year.
• Long-Term Deferred Tax slipped to $1.5 billion in Q1 2026, from $1.5 billion in the prior quarter.
• Over five years, Long-Term Deferred Tax peaked at $1.5 billion in Q1 2024 and troughed at $1.4 billion in Q2 2025.
• A 5-year average of $1.5 billion and a median of $1.5 billion in 2025 frame the typical range for Long-Term Deferred Tax.
• Annual changes were most pronounced in 2023 — Long-Term Deferred Tax advanced 4.72% — and 2025, when it decreased 7.64%.
• Tracing BMRN's Long-Term Deferred Tax over 5 years: stood at $1.5 billion in 2022, then rose by 2.68% to $1.5 billion in 2023, then dropped by 3.65% to $1.5 billion in 2024, then advanced by 1.3% to $1.5 billion in 2025, then slipped by 0.54% to $1.5 billion in 2026.
• Business Quant data shows BMRN's Long-Term Deferred Tax at $1.5 billion in Q1 2026, $1.5 billion in Q4 2025, and $1.5 billion in Q3 2025.